NEW YORK, Jan. 5, 2016 /PRNewswire/ -- Aisling Capital, a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies, announced that Eric Aguiar, MD has joined the firm as a Partner. Dr. Aguiar, who brings to Aisling experience in drug development, commercialization and strategic leadership, will invest in biopharma opportunities across a range of therapeutic areas and stages of development.
"We are delighted to welcome Eric to the team," said Steve Elms, Managing Partner at Aisling Capital. "Many of us have had the pleasure of working with Eric over the years, witnessing first-hand the business acumen and drug development and commercial expertise that he brings to each endeavor--and we're thrilled he'll now be applying those strengths as a member of Aisling's investing practice. His proven track record as an operator and entrepreneur, coupled with his extensive network across the healthcare industry, will also make him a highly valued resource to our portfolio." "Eric has over 20 years of experience in the healthcare industry in a variety of clinical, business, strategy, product and technology leadership roles. We are delighted to welcome him to Aisling Capital," said Drew Schiff, Managing Partner at Aisling Capital.
Prior to joining Aisling, Dr. Aguiar was a Partner at Thomas, McNerney & Partners and before that he was a Managing Director of HealthCare Ventures, both healthcare focused venture capital firms.
"I am very excited to join Aisling Capital after eight years at Thomas McNerney & Partners," said Dr. Aguiar. "Aisling's late-stage investment approach is one that I believe will continue to provide strong investment opportunities. I look forward to working with Steve, Drew and the team."
Dr. Aguiar currently sits on the board of Invitae Corporation (formerly Locus Development, Inc.). His prior board seats have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc. (acquired by Allergan), Vaxinate, Inc., Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson). Dr. Aguiar was CEO of Genovo, Inc. (acquired by Targeted Genetics), a biopharmaceuticals company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. (acquired by Watson Pharmaceuticals). Dr. Aguiar was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. He is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Dr. Aguiar received his Medical Degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. Dr. Aguiar was also a Luce Fellow and is a Chartered Financial Analyst.
About Aisling Capital
Aisling Capital is a leading investment firm that invests in products, technologies, and global businesses that advance health. Aisling Capital is led by a group of investment professionals with diverse backgrounds in industry, science, and finance. The team's complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aisling-capital-welcomes-eric-aguiar-as-partner-300199673.html
SOURCE Aisling Capital
